Long-term safety of high-dose whole pelvic IMRT for high-risk localized prostate cancer through 10-year follow-up-Reference-Cited by-同舟云学术

Long-term safety of high-dose whole pelvic IMRT for high-risk localized prostate cancer through 10-year follow-up

Published:2021-08-02 Issue:11 Volume:26 Page:2113-2122
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Aizawa Rihito,Nakamura Kiyonao,Norihisa Yoshiki,Ogata Takashi,Inoue Takahiro,Yamasaki Toshinari,Kobayashi Takashi,Akamatsu Shusuke,Ogawa Osamu,Mizowaki Takashi^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s10147-021-02002-x.pdf

Reference24 articles.

1. National Comprehensive Cancer network (2019) NCCN Guidelines; prostate cancer version 2.2019. In: The category of prostate cancer. https://www.nccn.org/guidelines/category_1 Accessed April 17 2019

2. Asbell SO, Martz KL, Shin KH et al (1998) Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG #77-06, a phase III study for T1BN0M0 (A2) and T2N0M0 (B) prostate carcinoma. Int J Radiat Oncol Biol Phys 40(4):769–782. https://doi.org/10.1016/s0360-3016(97)00926-7

3. Pommier P, Chabaud S, Lagrange JL et al (2016) Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the GETUG-01 randomized study. Int J Radiat Oncol Biol Phys 96(4):759–769. https://doi.org/10.1016/j.ijrobp.2016.06.2455

4. Roach M, Moughan J, Lawton CAF et al (2018) Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. Lancet Oncol 19(11):1504–1515. https://doi.org/10.1016/s1470-2045(18)30528-x

5. Tharmalingam H, Choudhury A, Van Herk M et al (2019) New approaches for effective and safe pelvic radiotherapy in high-risk prostate cancer. Nat Rev Urol 16(9):523–538. https://doi.org/10.1038/s41585-019-0213-3

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The real prevalence and clinical courses of non-metastatic castration-resistant prostate cancer: A retrospective single-institutional study;2024-02-07

2. Prospective results for 5-year survival and toxicity of moderately hypofractionated radiotherapy with simultaneous integrated boost (SIB) in (very) high-risk prostate cancer;Clinical and Translational Radiation Oncology;2024-01

3. Outcomes in patients with high- and very high-risk localized prostate cancer treated with definitive IMRT and long-term hormone therapy;Japanese Journal of Clinical Oncology;2023-12-23

4. Long-term outcomes of whole-pelvis radiation therapy using volumetric modulated arc therapy for high-risk prostate cancer;Journal of Radiation Research;2023-09-01

5. Clinical significance of IDC‐P as predictive factor after intensity‐modulated radiation therapy;Cancer Science;2022-05-19